Brief: Charles River Laboratories Provides Business Updates

Charles River Laboratories International

12/01/2026 21:43

Jan 12 (Reuters) - Charles River Laboratories International Inc CRL.N:

CHARLES RIVER LABORATORIES PROVIDES BUSINESS UPDATES

CHARLES RIVER LABORATORIES INTERNATIONAL INC: SIGNS AGREEMENT TO ACQUIRE K.F. (CAMBODIA) LTD. TO FURTHER STRENGTHEN DSA SUPPLY CHAIN

CHARLES RIVER LABORATORIES INTERNATIONAL - DEAL TO BE ACCRETIVE TO ADJUSTED EARNINGS PER SHARE BY ABOUT $0.25 IN 2026 AND APPROXIMATELY $0.60 IN 2027

CHARLES RIVER LABORATORIES INTERNATIONAL INC - PROPOSED ACQUISITION VALUED AT $510 MILLION

CHARLES RIVER LABORATORIES INTERNATIONAL INC - K.F. IS NOT EXPECTED TO GENERATE MEANINGFUL THIRD-PARTY REVENUE GOING FORWARD

CHARLES RIVER LABORATORIES INTERNATIONAL INC - TO BUY REMAINING 79% OF PATHOQUEST SAS

CHARLES RIVER LABORATORIES INTERNATIONAL INC - PATHOQUEST ACQUISITION VALUED AT €51.6 MILLION

CHARLES RIVER LABORATORIES INTERNATIONAL INC - PATHOQUEST IS EXPECTED TO GENERATE ANNUAL REVENUE OF ABOUT $15 TO $20 MILLION IN 2026

CHARLES RIVER LABORATORIES INTERNATIONAL - PATHOQUEST DEAL NOT EXPECTED TO HAVE MATERIAL IMPACT ON CHARLES RIVER'S 2026 OR 2027 FINANCIAL RESULTS

CHARLES RIVER LABORATORIES INTERNATIONAL: SEES TOP END OF GUIDANCE RANGE FOR 2026 ORGANIC REVENUE GROWTH WILL BE AT LEAST FLAT

Source text: ID:nBw4f4gPha

Further company coverage: CRL.N

 ((Reuters.Briefs@thomsonreuters.com;))